Page 162 - 2021_04-Haematologica-web

J.P. Loftus et al.
Selective killing of mixed lineage leukemia
cells by a potent small-molecule DOT1L
inhibitor. Cancer Cell. 2011;20(1):53-65.
55. Shukla N, Wetmore C, O'Brien MM, et al. Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in chil- dren with relapsed or refractory MLL-r acute
leukemia. Blood. 2016;128(22):2780.
56. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatu- momab in pediatric patients with
relapsed/refractory acute lymphoblasticl eukemia. J Clin Oncol. 2016;34(36):4381- 4389.
57. Driessen EM, van Roon EH, Spijkers- Hagelstein JA, et al. Frequencies and prog- nostic impact of RAS mutations in MLL- rearranged acute lymphoblastic leukemia in infants. Haematologica. 2013;98(6):937-944.
58. Prelle C, Bursen A, Dingermann T, Marschalek R. Secondary mutations in t(4;11) leukemia patients. Leukemia.
2013;27(6):1425-1427.
59. Kerstjens M, Driessen EM, Willekes M, et al.
MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. Oncotarget. 2017; 8(9):14835-14846.
60.Cremer A, Ellegast JM, Alexe G, et al. Resistance mechanisms to SYK inhibition in acute myeloid leukemia. Cancer Discov. 2020; 10(2):214-231.
1078
haematologica | 2021; 106(4)